Hypogonadism Completed Phase 4 Trials for Testosterone (DB00624)

IndicationStatusPhase
DBCOND0009256 (Hypogonadism)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02937740Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢Treatment
NCT03619330Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.Treatment
NCT00194675TRADE-Testosterone Replacement and Dutasteride EffectivenessTreatment
NCT02366975TRT on BPH Hypoganadal MetS Patients. Florence-PROTESTTreatment
NCT00349362Testosterone for Men With Insulin Treated Type 2 DiabetesTreatment
NCT00421460The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile DysfunctionTreatment
NCT01107067Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With HypogonadismScreening
NCT01123278Testosterone Replacement in Metabolic Syndrome and InflammationTreatment
NCT01127659Testosterone Replacement in Men With Diabetes and ObesityTreatment
NCT01143818ESPRIT Study in Hypogonadal Men
NCT01160341Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With HypogonadismScreening
NCT01560546Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)Treatment
NCT01893281The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone GelTreatment
NCT02111434Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron TreatmentScreening
NCT02111473The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic HypogonadismTreatment